US Department Of Health And Human Services Grants Orphan Drug Status To BioCancell’s Ovarian Cancer Drug
Submitted by MedicalReplies on Tuesday, 25 August 2009No Comment
Tikcro Technologies (PK: TIKRF) announced that the United States (”US”) Department of Health and Human Services (”HHS”) has granted orphan drug status to BioCancell’s BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer. Tikcro holds 36% of Biocancell (after conversion of notes and exercise of warrants), and 27% on a fully diluted basis.
See the original post:
US Department Of Health And Human Services Grants Orphan Drug Status To BioCancell’s Ovarian Cancer Drug
Leave your response!